Navigation Links
New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
Date:8/20/2007

Mark S. George, M.D. Named Editor-in-Chief of New Brain Stimulation Journal

CHARLESTON, S.C., Aug. 20 /PRNewswire/ -- Medical University of South Carolina (MUSC) today announced the results of a functional MRI (fMRI) study examining the effects of VNS (Vagus Nerve Stimulation) Therapy(TM) for patients with treatment-resistant depression (TRD). The study, led by Ziad Nahas, M.D., associate professor, MUSC Department of Psychiatry, appears in the August 2007 issue of peer-reviewed Neuropsychopharmacology. The results show that VNS Therapy modulates areas of the brain that control mood. The researchers also identified variables, such as length of use, strength of stimulation and level of depression, to better understand the impact of VNS Therapy.

"These data provide further insight into VNS therapy's distinct mechanism of action and support its previously demonstrated long-term, sustained efficacy," Nahas said. "We are encouraged to see the unique benefit VNS therapy may bring to patients with one of the most difficult-to-treat forms of depression and are excited to continue neurostimulation research at MUSC."

The study illustrates that VNS Therapy modifies activity of the medial prefrontal cortex, the same area of the brain targeted by many antidepressant medications and electroconvulsive therapy (ECT). A critical time for such effective modulation occurs approximately at 30 weeks of treatment. Such modulation could support VNS Therapy's unique mechanism of action as a long- term treatment for chronic or recurrent depression and directly corresponds with the timeframe in which patients typically experience a decrease in symptoms. Further analysis of the data demonstrates that modulation of the brain is a dynamic process that over time leads to indirectly related improved response with continued use. These findings corroborate an earlier MUSC-led study that revealed approximately two-thirds of patients who respond to VNS Therapy continue to experi
'/>"/>

SOURCE Medical University of South Carolina

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... WORCESTER, Mass. and TORONTO ... ( www.generex.com ) (OTCQB:GNBT) today announced that it intends ... securities it receives upon completion of a definitive licensing ... to Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). ... a non-binding letter of intent in respect of the ...
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
(Date:5/5/2015)... The PracticeMatch Career Fair will take ... at the Rochester Marriott, 1001 First Avenue SW, Rochester, MN ... opportunities will be attending from across the country. All specialties ... raffle prize drawings. , Leslie Thompson, Director of Career Fairs ... to hold a career fair. In the metropolitan area there ...
(Date:5/5/2015)... 05, 2015 The report ... provides comparative analysis on the therapeutic development ... pipelines by identifying new targets and MOAs ... report is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html ... Fibrosis – Pipeline Review, H2 2014 report ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 With the ... clothing and enjoying the feel of warm breezes on bare ... to strategies on how to look their best in shorts, ... “More and more people are turning to laser treatments for ... aesthetician of Simply Posh Aesthetic Spa . “They're all ...
(Date:5/5/2015)... There have been numerous attempts to ... on personal lines (home, auto, etc). Now, for the ... (NDOI.com) has created an online vehicle for more than ... present their expertise in all realms of insurance directly ... and two-fold. , First, the online, searchable database improves ...
(Date:5/4/2015)... Hoersholm, Denmark (PRWEB) May 05, 2015 ... pathology, announces today the closing of a private round ... amount is undisclosed. , This investment will assist Visiopharm ... as a market leader for image analysis driven diagnostic ... see how much Visiopharm's ONCOtopix™ Dx solution ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 3Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 3Health News:Laser Hair Removal: Tips for Summertime Grooming 2Health News:Laser Hair Removal: Tips for Summertime Grooming 3Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 3Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 2Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 3
... fears of large scale global outbreak of bird flu that ... people have started stock piling and storing stocks of bird ... and Human Services (HHS) plans to stock vaccines and anti-viral ... avian influenza has infected more than 100 people in Asia ...
... voice concerns over the use of Jab (MMR Vaccines), there ... wide which is the only source of protection for children’s ... of about 80% in the usage // of vaccine ... world wide concerns regarding the use of MMR vaccine as ...
... Exposure to lead in early childhood and adolescence may ... cognitive abilities. // , ,Both lead exposure and ... adults. The study indicates that the interaction between lead ... in working age adults may lead to diminishing cognitive ...
... Seasonal Affective Disorder (SAD) has been found to be affected ... emphasising the importance of sunlight for health. // ... a drop in physical energy, increased appetite, and increased need ... complex inter relation between melatonin and serotonin. , ,Our ...
... India has an estimated 5.1 million HIV-infected people, next only ... Shillong (capital of the northeastern state of Meghalaya.) said that ... India in three to four years., ,The northeast state ... India and the AIDS virus has now many victims in ...
... leading to a condition of early atherosclerosis, according to a ... women in the same // situation do not show ... University of Helsinki in Finland had found increased thickness of ... the head, in men who reported having low job control ...
Cached Medicine News:Health News:Increased demand for Bird flu anti-viral drug world wide 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: